专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014030780A1 SCREENING AND ENGINEERING METHOD OF SUPER-STABLE IMMUNOGLOBULIN VARIABLE DOMAINS AND THEIR USES 审中-公开
标题翻译：超稳定免疫球蛋白可变区的筛选和工程方法及其用途
公开(公告)号：WO2014030780A1
公开(公告)日：2014-02-27
申请号：PCT/KR2012/006680
申请日：2012-08-22
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , LIM, Hyung-Kwon , KIM, Sung Geun , PARK, Young Seoub , NAM, Hyo Jung , KIM, Dong-Sik , PARK, Jae Chan , YOON, Yeup
发明人： LIM, Hyung-Kwon , KIM, Sung Geun , PARK, Young Seoub , NAM, Hyo Jung , KIM, Dong-Sik , PARK, Jae Chan , YOON, Yeup
IPC分类号： C12N15/62 , C12N15/63 , C07K19/00 , C12N15/13 , C07K16/28 , G01N33/53
CPC分类号： G01N33/6857 , C07K16/00 , C07K16/18 , C07K16/32 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/94 , C07K2319/00 , C07K2319/10 , C40B40/10 , G01N2500/00
摘要： There are provided a method named Tat-associated protein engineering (TAPE), of screening a target protein having higher solubility and excellent thermostability, in particular, an immunoglobulin variable domain (VH or VL) derived from human germ cells, by preparing a gene construct where the target protein and an antibiotic -resistant protein are linked to a Tat signal sequence, and then expressing this within E. coli , and human or engineered VH and VL domain antibodies and human or engineered VH and VL domain antibody scaffolds having solubility and excellent thermostability, which are screened by the TAPE method. There are also provided a library including random CDR sequences in the human or engineered VH or VL domain antibody scaffold screened by the TAPE method, and a preparing method thereof. There are also provided a VH or VL domain antibody having binding ability to the target protein screened by using the library, and a pharmaceutical composition including the domain antibody.
摘要翻译：提供了一种称为Tat相关蛋白工程（TAPE）的方法，通过制备基因构建体筛选具有较高溶解性和优异热稳定性的靶蛋白，特别是衍生自人生殖细胞的免疫球蛋白可变结构域（VH或VL）其中靶蛋白和抗生素抗性蛋白与Tat信号序列连接，然后在大肠杆菌内表达，以及人或工程化的VH和VL结构域抗体以及具有溶解度和优异性的人或工程改造的VH和VL结构域抗体支架热稳定性，由TAPE方法进行筛选。还提供了一种文库，其包括通过TAPE方法筛选的人或工程化的VH或VL结构域抗体构架中的随机CDR序列及其制备方法。还提供了通过使用文库筛选的靶蛋白具有结合能力的VH或VL结构域抗体和包含结构域抗体的药物组合物。

2. 发明申请

WO2009038266A1 METHOD FOR ENHANCING SERUM STABILITY AND LOWERING IMMUNE RESPONSE OF SIRNA DOWN-REGULATING GENE EXPRESSION OF HBV OR HCV 审中-公开
标题翻译：用于增强血清稳定性和降低SIRNA下调HBV基因表达的免疫应答方法
公开(公告)号：WO2009038266A1
公开(公告)日：2009-03-26
申请号：PCT/KR2008/002589
申请日：2008-05-08
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KIM, Soo In , SHIN, Duckhyang , LEE, Hyeon , KIM, Meehyein , PARK, Doo-Hong , YOON, Yeup
发明人： KIM, Soo In , SHIN, Duckhyang , LEE, Hyeon , KIM, Meehyein , PARK, Doo-Hong , YOON, Yeup
IPC分类号： A61K48/00 , A61P1/16 , C12N15/11 , C07H21/02 , C12N15/09 , C12N15/51
CPC分类号： C07H21/02 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12N2320/51 , C12N2320/53 , C12N2310/3521
摘要： A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.
摘要翻译：提供了一种提高针对乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）的病毒基因表达介导RNA干扰（RNAi）的小干扰核糖核酸（siRNA）的血清稳定性和降低免疫刺激性的方法。

3. 发明申请

WO2009008645A3 LINEAR DOUBLE-STRANDED RNA MOLECULE INTERFERING WITH DIFFERENT TARGET GENES 审中-公开
公开(公告)号：WO2009008645A3
公开(公告)日：2009-01-15
申请号：PCT/KR2008/003982
申请日：2008-07-07
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KIM, Meehyein , SHIN, Duckhyang , LEE, Hyeon , KIM, Soo In , YOON, Yeup
发明人： KIM, Meehyein , SHIN, Duckhyang , LEE, Hyeon , KIM, Soo In , YOON, Yeup
IPC分类号： C12N15/09 , C12P19/34
摘要： A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.

4. 发明申请

WO2007011166A1 MUTANT OF GRANULOCYTE-COLONY STIMULATING FACTOR(G-CSF) AND CHEMICALLY CONJUGATED POLYPEPTIDE THEREOF 审中-公开
标题翻译：粒细胞集落刺激因子（G-CSF）和化学结合多肽的突变体
公开(公告)号：WO2007011166A1
公开(公告)日：2007-01-25
申请号：PCT/KR2006/002841
申请日：2006-07-19
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KANG, Kwan-Yub , HONG, Jeong-Woon
发明人： KANG, Kwan-Yub , HONG, Jeong-Woon
IPC分类号： C07K14/535 , A61K47/48
CPC分类号： C07K14/535 , A61K47/60
摘要： Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (GIy) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF. Further, the invention provides a chemically conjugated mutant G-CSF to which biocompatible polymer such as polyethylene glycol (PEG) was attached at the cysteine residue, which was introduced by the substitution or insertion mutation, increasing its in vivo retention time without reducing in vivo biological activity due to the conjugation with the biocompatible polymer, thereby ultimately extending the in vivo biological activity.
摘要翻译：提供设计用于特定化学共轭的人粒细胞集落刺激因子（G-CSF）的突变体，以及用作癌症治疗中的佐剂的化学共轭物。本发明提供了G-CSF的突变体，其中包含SEQ ID NO：1中鉴定的氨基酸序列的G-CSF的第133位的苏氨酸（Thr）残基被半胱氨酸（Cys）残基取代。此外，本发明提供了G-CSF的突变体，其中将半胱氨酸（Cys）残基插入在135位的甘氨酸（Gly）残基和G-CSF的第136位的丙氨酸（Ala）残基之间。此外，本发明提供了在半胱氨酸残基处连接生物相容性聚合物如聚乙二醇（PEG）的化学偶联的突变体G-CSF，其通过取代或插入突变引入，增加其体内保留时间而不降低体内由于与生物相容性聚合物共轭而产生的生物活性，从而最终延长了体内的生物活性。

5. 发明申请

WO2006129995A1 STABILIZED PARATHYROID HORMONE COMPOSITION COMPRISING PARATHYROID HORMONE, BUFFER AND STABILIZING AGENT 审中-公开
标题翻译：包含PARATHYROID HORMONE，缓冲剂和稳定剂的稳定化的PARATHYROID HORMONE组合物
公开(公告)号：WO2006129995A1
公开(公告)日：2006-12-07
申请号：PCT/KR2006/002167
申请日：2006-06-05
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KANG, Kwan-Yub , PARK, Doo-Hong , JEON, Jung-Won , LEE, Yong-Seok
发明人： KANG, Kwan-Yub , PARK, Doo-Hong , JEON, Jung-Won , LEE, Yong-Seok
IPC分类号： A61K38/22 , A61P5/18
CPC分类号： A61K38/29 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/26
摘要： Disclosed relates to a stabilizied parathyroid hormone (PTH) comprising a buffer and a stabilizing agent and, more particularly, to a stabilized PTH composition in which succinic acid, malic acid, histidine or ammonium bicarbonate is used as the buffer and sorbitol or mannitol is used as the stabilizing agent. The PTH composition of the present invention can be used to formulate stably PTH protein that is much more unstable to be readily decomposed than normal low molecular weight drugs.
摘要翻译：涉及包含缓冲液和稳定剂的稳定化甲状旁腺激素（PTH），更具体地说，涉及使用琥珀酸，苹果酸，组氨酸或碳酸氢铵作为缓冲液并使用山梨糖醇或甘露糖醇的稳定的PTH组合物作为稳定剂。本发明的PTH组合物可用于配制比正常低分子量药物更不稳定的易分解的PTH蛋白。

6. 发明申请

WO2006096018A1 SMALL INTERFERING RNA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS B COMPRISING THE SAME 审中-公开
标题翻译：用于治疗包含其中的乙型肝炎病毒的小干扰RNA和药物组合物
公开(公告)号：WO2006096018A1
公开(公告)日：2006-09-14
申请号：PCT/KR2006/000837
申请日：2006-03-09
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KIM, Meehyein , SHIN, Duckhyang , KIM, Soo In , PARK, Mahnhoon
发明人： KIM, Meehyein , SHIN, Duckhyang , KIM, Soo In , PARK, Mahnhoon
IPC分类号： C12N15/11 , C12N15/51 , C12N15/09
CPC分类号： C12N15/111 , C12N15/1131 , C12N2310/111 , C12N2310/14 , C12N2330/30
摘要： The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention.
摘要翻译：本发明涉及RNA干扰介导的通过短干扰RNA（siRNA）分子对乙型肝炎病毒（HBV）的抑制。特别地，作为双链RNA的本发明的siRNA涉及指导病毒RNA在哺乳动物细胞中的序列特异性降解。公开了编码RNA分子和合成的siRNA分子的DNA载体以及通过施用本发明的RNA分子来抑制HBV基因表达和病毒复制的治疗性治疗方法。

7. 发明申请

WO2011129468A9 HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME 审中-公开
公开(公告)号：WO2011129468A9
公开(公告)日：2011-10-20
申请号：PCT/KR2010/002298
申请日：2010-04-14
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , LEE, Kyuhyun , YUN, Seongtae , KOH, Daekyung , LEE, Hong-Kyu , JO, Eui-Cheol
发明人： LEE, Kyuhyun , YUN, Seongtae , KOH, Daekyung , LEE, Hong-Kyu , JO, Eui-Cheol
IPC分类号： C07K14/075 , C12N15/34 , C12N15/861
摘要： Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.

8. 发明申请

WO2009102085A1 EXPRESSION VECTOR SUITABLE FOR EXPRESSION OF A CODING SEQUENCE FOR GENE THERAPY 审中-公开
标题翻译：用于表达基因治疗编码序列的表达载体
公开(公告)号：WO2009102085A1
公开(公告)日：2009-08-20
申请号：PCT/KR2008/000870
申请日：2008-02-14
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KOH, Daekyung , LEE, Kyuhyun , LEE, Hyeon , YUN, Seongtae , JO, Eui-Cheol
发明人： KOH, Daekyung , LEE, Kyuhyun , LEE, Hyeon , YUN, Seongtae , JO, Eui-Cheol
IPC分类号： C12N15/79 , C12N15/67
CPC分类号： C12N15/63
摘要： Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.
摘要翻译：提供了具有转录调节元件的新组合的基因治疗的表达载体，其包括启动子，增强子，内含子，非翻译区（UTR）和基因座控制区（LCR）。表达载体能够持续表达肝组织特异性基因，因此可有效用于治疗血栓形成，血友病，肝癌等。

9. 发明申请

WO2008153366A2 METHOD FOR MANUFACTURING ACTIVE RECOMBINANT BLOOD COAGULATION FACTOR IX 审中-公开
标题翻译：制备活性重组血液凝血因子IX的方法
公开(公告)号：WO2008153366A2
公开(公告)日：2008-12-18
申请号：PCT/KR2008/003377
申请日：2008-06-16
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , KIM, Jung-Seob , LIM, Inhwan , CHOI, Murim , LEE, Gue-Hwa , YOON, Yeup
发明人： KIM, Jung-Seob , LIM, Inhwan , CHOI, Murim , LEE, Gue-Hwa , YOON, Yeup
IPC分类号： C12N15/85 , C12N15/11
CPC分类号： C12N9/647 , C12N9/644 , C12Y304/21022
摘要： The present invention provides an expression vector producing a recombinant blood coagulation factor IX (FIX), an animal cell line transfected with the expression vector, an optimized medium for animal cell culture able to maximize the production of active FIX (aFIX), and an optimized culture method to culture the animal cell line in the optimized medium.
摘要翻译：本发明提供产生重组血液凝固因子IX（FIX）的表达载体，用表达载体转染的动物细胞系，能够使活性FIX（aFIX）产生最大化的动物细胞培养物的优化培养基，以及优化的培养方法，在优化培养基中培养动物细胞系。

10. 发明申请

WO2008085008A1 T-CELL INHIBITING COMPOUNDS AND THEIR USE FOR THE TREATMENT OF T-CELL-MEDIATED DISEASES 审中-公开
标题翻译： T细胞抑制化合物及其用于治疗T细胞介导性疾病的用途
公开(公告)号：WO2008085008A1
公开(公告)日：2008-07-17
申请号：PCT/KR2008/000195
申请日：2008-01-11
申请人： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE , WON, Jonghwa , JUNG, Eun Joo , HUR, Minkyu , KIM, Sungjoo , KIM, Young Lim , PARK, Doo-Hong , LEE, Ge Hyeong , KIM, Ikyon , YOO, Sung-Eun , KIM, Ji Young , WON, Hye Kyoung
发明人： WON, Jonghwa , JUNG, Eun Joo , HUR, Minkyu , KIM, Sungjoo , KIM, Young Lim , PARK, Doo-Hong , LEE, Ge Hyeong , KIM, Ikyon , YOO, Sung-Eun , KIM, Ji Young , WON, Hye Kyoung
IPC分类号： C07D235/18 , C07D235/26 , C07D401/12 , C07D413/12 , A61K31/416 , A61P37/00
CPC分类号： C07D233/90 , C07D233/84 , C07D401/06 , C07D405/04 , C07D409/04 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds of formula IA or IB. The present invention also concerned to a method of treating immunologic diseases or pathological conditions in association with T cell involving an immunologic component using T-cell inhibitors, optionally in combination with one or more other drugs selected from steroids, DMARDs, NSAIDs, immunosuppressive, and biological modifiers, pharmaceutical compositions comprising said compounds of formula IA or IB together with said other drugs, and the use of T-cell inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
摘要翻译：本发明涉及式IA或IB的化合物。本发明还涉及一种使用T细胞抑制剂治疗与T细胞相关的免疫学疾病或病理状态的方法，所述T细胞抑制剂任选地与一种或多种其它选自类固醇，DMARD，NSAID，免疫抑制剂和生物改性剂，包含式IA或IB的所述化合物与所述其它药物的药物组合物，以及T细胞抑制剂在制备用于治疗免疫学疾病或涉及免疫组分的病理状况的药物组合物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式